EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Neuroscience Research -
Location
-
Principal Investigator
Ammar Hussain -
Sponsor
Stoke Therapeutics
To assess the effect of zorevunersen to reduce the frequency of major motor seizures in patients with DS.
Enrollment Form
This study is currently enrolling.